<- Go Home

TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Market Cap

$39.6M

Volume

182.2K

Cash and Equivalents

$29.7M

EBITDA

-$34.4M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$52.2M

Profit Margin

67.73%

52 Week High

$3.20

52 Week Low

$0.86

Dividend

N/A

Price / Book Value

25.89

Price / Earnings

-1.12

Price / Tangible Book Value

391.42

Enterprise Value

$51.4M

Enterprise Value / EBITDA

-1.51

Operating Income

-$35.5M

Return on Equity

1654.21%

Return on Assets

-38.68

Cash and Short Term Investments

$29.7M

Debt

$41.5M

Equity

$1.6M

Revenue

$77.1M

Unlevered FCF

N/A

Sector

Health Care Equipment and Supplies

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches